UBS Group
CNTB

UBS Group’s Connect Biopharma Holdings CNTB Stock Holding History

UBS Group’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$158K Buy
66,451
+66,418
+201,267% +$161K ﹤0.01% 6929
2026
Q1 		$86 Sell
33
-3,132
-99% -$8.16K ﹤0.01% 10139
2025
Q4 		$8.93K Buy
3,165
+2,964
+1,475% +$6.32K ﹤0.01% 8320
2025
Q3 		$304 Buy
201
+159
+379% +$281 ﹤0.01% 9749
2025
Q2 		$41 Sell
42
-8,697
-100% -$6.93K ﹤0.01% 10067
2025
Q1 		$4.81K Buy
8,739
+4,006
+85% +$3.71K ﹤0.01% 9062
2024
Q4 		$6.53K Buy
+4,733
New +$5.45K ﹤0.01% 8554
2023
Q2 		– Sell
-9,336
Closed -$9.34K – 9004
2023
Q1 		$9.34K Sell
9,336
-8,798
-49% -$9.6K ﹤0.01% 7664
2022
Q4 		$15.8K Buy
18,134
+17,638
+3,556% +$14.5K ﹤0.01% 7949
2022
Q3 		$1K Sell
496
-104,689
-100% -$126K ﹤0.01% 9937
2022
Q2 		$91K Buy
105,185
+103,324
+5,552% +$152K ﹤0.01% 5500
2022
Q1 		$6K Buy
1,861
+1,080
+138% +$4.56K ﹤0.01% 8957
2021
Q4 		$4K Buy
781
+346
+80% +$3.85K ﹤0.01% 9504
2021
Q3 		$11K Buy
+435
New +$9.84K ﹤0.01% 7868

Other funds holding CNTB

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

UBS Group's CNTB Position: Q2 2026 in Review

UBS Group increased its Connect Biopharma Holdings (CNTB) stake by 201,267% in Q2 2026, buying an estimated $161K and bringing the position to 66,451 shares worth $158K. The position accounts for ﹤0.01% of the portfolio, ranked #6929.

UBS Group first reported a position in CNTB in Q3 2021 and has held it in 14 quarters since. 56 funds tracked by Wall St. Rank hold CNTB as of Q2 2026.

  • UBS Group held 66,451 shares of Connect Biopharma Holdings worth $158K as of Q2 2026.
  • UBS Group bought 66,418 Connect Biopharma Holdings shares in Q2 2026, an estimated $161K.
  • Connect Biopharma Holdings made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6929 holding.
  • UBS Group first reported a position in Connect Biopharma Holdings in Q3 2021 and has held it in 14 quarters since.
  • 56 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.